Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic ...

Figure 1. The formation of AA and LA metabolites (ASA-COX―acetylsalicylic acid (aspirin) cyclooxygenase, PGG―prostaglandin G, LOX―lipoxygenase, HETE―hydroxyeicosatetraenoic acids, ...

Benign prostatic hyperplasia (BPH) is a prevalent condition characterised by the non-malignant enlargement of the prostate gland, which frequently precipitates lower urinary tract symptoms (LUTS).

Extracts of the berries of saw palmetto, a small palm tree native to the southeastern U.S., are used widely to treat benign prostatic hyperplasia (BPH). In this randomized trial conducted in ...

Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. The Food and Drug Administration (FDA) has approved Entadfi ...

An enlarged prostate—also known as benign prostatic hyperplasia (BPH)—is a natural sign of aging that affects half of all men over the age of 40. The good news is this condition does not increase your ...

In a trial, vibegron 75 mg once daily meaningfully improved key OAB symptoms in men receiving benign prostatic hyperplasia treatments. Vibegron reduces storage symptoms of overactive bladder (OAB) in ...

Investigators compared prostatic artery embolization against a combination of an alpha blocker and 5-alpha reductase inhibitor for BPH. Prostatic artery embolization (PAE) yields greater clinical ...

Patients with gout, especially those younger than 60 years, have an increased risk for benign prostatic hyperplasia (BPH), according to a study published online Dec. 26 in Diagnostics. Woo Jin Bang, ...

These new findings are important as α-blockers (ABs) are the most prescribed class of medications for patients with benign prostatic hyperplasia (BPH), but the cardiovascular safety profile of this ...